Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can special lenses plus eye drops stop Kids' myopia from getting worse?

NCT ID NCT06358755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests whether combining special glasses (that create optical defocus) with low-dose atropine eye drops can better control myopia (nearsightedness) in children aged 7 to 12. Over 18 months, researchers will measure changes in eye prescription and eye length. The goal is to find a more effective way to slow myopia progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose atropine (0.01%) eye drops
What this could lead to
If successful, this combination approach could offer a more effective way to slow down worsening nearsightedness in children, potentially reducing the need for stronger glasses later.
What could go wrong
This is a relatively small, early-stage trial (112 children) and results may not apply to all ethnicities or ages. The atropine drops can cause side effects like light sensitivity or blurred near vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age at enrollment: 7 to 12 years * Ethnicity: Hong Kong Chinese * Myopia: -0.75D (in spherical equivalent) or above in both eyes * Astigmatism: -1.50D or less in both eyes * Anisometropia: 1.50D or less (in spherical equivalent) between two eyes * Best corrected monocular visual acuity (VA): 0.04 logMAR or better * Ocular health: No abnormalities in both internal and external ocular health * Systemic health: No abnormalities such as cardiac and respiratory diseases * Binocular vision: No strabismus, diplopia, suppression and other binocular abnormalities * Normal colour vision * No previous refractive surgery or use of myopic control interventions, such as atropine, orthokeratology, and specialized spectacle lenses and contact lenses for myopic control * Able to wear the prescribed spectacles * No known allergy to atropine Exclusion Criteria: * Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.) * Previous intraocular or corneal surgery * Colour vision deficiencies * Systemic disease that may affect vision, vision development (e.g. diabetes mellitus, hypertension, Down syndrome, etc.) * Systemic disease that are contradictory to atropine (e.g. asthma, cardiac diseases, etc.) * Previous gas permeable, soft bifocal, or orthokeratology contact lenses wear or bifocal / progressive addition lens spectacles wear or use of atropine or pirenzepine (longer than one month of usage) * Previous or current participation in myopia control studies * Allergy to cyclopentolate hydrochloride or atropine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Myopia Research, The Hong Kong Polytechnic University and Department of Ophthalmology, The University of Hong Kong

    Hong Kong, No postcode, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.